Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc (NQ: AGEN )

6.560 +0.600 (+10.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 760,652
Open 6.010
Bid (Size) 6.450 (1)
Ask (Size) 6.560 (1)
Prev. Close 5.960
Today's Range 5.990 - 6.650
52wk Range 4.775 - 32.00
Shares Outstanding 348,875,959
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
From Agenus Inc.
Via Business Wire
Agenus Faces Regulatory and Financial Challenges: Analyst Downgrades Stock Pending Trial Clarity
Agenus faces a setback as the FDA advises against accelerated approval for its immunotherapy combination, botensilimab and balstilimab, for relapsed/refractory microsatellite-stable colorectal cancer.... 
Via Benzinga
Exposures Product Safety

Performance

YTD
-59.01%
-59.01%
1 Month
-55.88%
-55.88%
3 Month
-20.96%
-20.96%
6 Month
-45.32%
-45.32%
1 Year
-78.13%
-78.13%

More News

Read More
AGEN Investors Have Opportunity to Join Agenus Inc. Securities Fraud Investigation with the Schall Law Firm
From Schall Law Firm
Via Business Wire
Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views
Via Benzinga
Topics Earnings
Exposures Financial
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Dow Dips 250 Points; US Weekly Jobless Claims Surge
Via Benzinga
Topics Stocks
Exposures US Equities
WBD Stock Pops as Warner Bros. Considers Streaming Spinoff
Via InvestorPlace
Agenus Loses More Than 50% Value On Thursday - Here's Why
Via Benzinga
Exposures Product Safety
Why Is NKGen Biotech (NKGN) Stock Up 18% Today?
Via InvestorPlace
Why Is Agenus (AGEN) Stock Down 55% Today?
Via InvestorPlace
US Stocks Edge Higher; D.R. Horton Posts Upbeat Earnings
Via Benzinga
Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer
From Agenus Inc.
Via Business Wire
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
From Agenus Inc.
Via Business Wire
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
From Agenus Inc.
Via Business Wire
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
From Agenus Inc.
Via Business Wire
Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50
From Agenus
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Agenus Announces Virtual Annual Shareholders Meeting
From Agenus Inc.
Via Business Wire
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
Via InvestorPlace
7 Biotech Stocks to Put on Your Breakthrough Radar
Via InvestorPlace
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Agenus Inc.
Via Business Wire
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
From Agenus Inc.
Via Business Wire
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
From Agenus Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.